Leo Vladovsky

BCF represented the CTI Life Sciences Fund III, L.P. in connection with the organization and financing of Oligon Therapeutics Inc., alongside Investissement Québec and the Fonds de solidarité des travailleurs et travailleuses du Québec (FTQ), for a total investment of USD 14 million. Oligon Therapeutics Inc. is an emerging biotechnology company pioneering the development of multi-target RNA-based drugs, offering innovative treatments in oncology, immunology, and other therapeutic areas.

Acted on behalf of Johal Holdings Inc. in connection with the acquisition of Industries Unicor Inc., a Québec-based company specializing in injection molding with an international presence in precision manufacturing across the industrial, automotive, medical sectors, and more. This transaction will enable Industries Unicor Inc. to accelerate its modernization, increase its production capacity, and invest further in local talent development, technology, and sustainable manufacturing practices.